AVAnna Valeria Vergoni

Anna Valeria Vergoni

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Anna Valeria Vergoni has a total of 136 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • CCAP regulates feeding behavior via the NPF pathway inDrosophilaadults

    by Michael J. Williams, Mehwish Akram, Deimante Barkauskaite, Sourabh Patil, Eirini Kotsidou, Sania Kheder, Giovanni Vitale, Monica Filaferro, Simone W. Blemings, Giulia Maestri, et al.

    The intake of macronutrients is crucial for the fitness of any animal and is mainly regulated by peripheral signals to the brain. How the brain receives and translates these peripheral signals or how these interactions lead to changes in feeding behavior is not well-understood. We discovered that 2 crustacean cardioactive peptide (CCAP)-expressing neurons in Drosophila adults regulate feeding behavior and metabolism. Notably, loss of CCAP, or knocking down the CCAP receptor (CCAP-R) in 2 dorsal median neurons, inhibits the release of neuropeptide F (NPF), which regulates feeding behavior. Furthermore, under starvation conditions, flies normally have an increased sensitivity to sugar; however, loss of CCAP, or CCAP-R in 2 dorsal median NPF neurons, inhibited sugar sensitivity in satiated and starved flies. Separate from its regulation of NPF signaling, the CCAP peptide also regulates triglyceride levels. Additionally, genetic and optogenetic studies demonstrate that CCAP signaling is necessary and sufficient to stimulate a reflexive feeding behavior, the proboscis extension reflex (PER), elicited when external food cues are interpreted as palatable. Dopaminergic signaling was also sufficient to induce a PER. On the other hand, although necessary, NPF neurons were not able to induce a PER. These data illustrate that the CCAP peptide is a central regulator of feeding behavior and metabolism in adult flies, and that NPF neurons have an important regulatory role within this system. Significance The ability of an animal to sense what to eat, such as carbohydrate-rich food, as well as to reject food that may be disadvantageous or even deadly is essential for survival and adaptation to metabolic demands compounded by continuous changes in the environment. Here we investigate evolutionarily conserved pathways central for either choosing or rejecting nutrients based on neuronal system interactions between internal signals and the external milieu. These pathways are likely to be necessary for the ability to perform quick adaptation to the immediate conditions and in general provide clues to the structure of the fly’s internal network governing nutrient sensing.


  • Open Access

    Adhesion GPCRs are widely expressed throughout the subsections of the gastrointestinal tract

    by Luca Badiali, Jonathan Cedernaes, Pawel K Olszewski, Olof Nylander, Anna V Vergoni, Helgi B Schiöth

    Background: G protein-coupled receptors (GPCRs) represent one of the largest families of transmembrane receptors and the most common drug target. The Adhesion subfamily is the second largest one of GPCRs and its several members are known to mediate neural development and immune system functioning through cell-cell and cell-matrix interactions. The distribution of these receptors has not been characterized in detail in the gastrointestinal (GI) tract. Here we present the first comprehensive anatomical profiling of mRNA expression of all 30 Adhesion GPCRs in the rat GI tract divided into twelve subsegments. Methods: Using RT-qPCR, we studied the expression of Adhesion GPCRs in the esophagus, the corpus and antrum of the stomach, the proximal and distal parts of the duodenum, ileum, jejunum and colon, and the cecum. Results: We found that twenty-one Adhesion GPCRs (70%) had a widespread (expressed in five or more segments) or ubiquitous (expressed in eleven or more segments) distribution, seven (23%) were restricted to a few segments of the GI tract and two were not expressed in any segment. Most notably, almost all Group III members were ubiquitously expressed, while the restricted expression was characteristic for the majority of group VII members, hinting at more specific/localized roles for some of these receptors. Conclusions: Overall, the distribution of Adhesion GPCRs points to their important role in GI tract functioning and defines them as a potentially crucial target for pharmacological interventions.


  • Can Leptin-Derived Sequence-Modified Nanoparticles Be Suitable Tools for Brain Delivery?

    by Giovanni Tosi, Luca Badiali, Barbara Ruozi, Anna Valeria Vergoni, Lucia Bondioli, Anna Ferrari, Francesco Rivasi, Flavio Forni, Maria Angela Vandelli

    In order to increase the knowledge on the use of nanoparticles (NPs) in brain targeting, this article describes the conjugation of the sequence 12-32 (g21) of leptin to poly-lactide-co-glycolide NPs. The capability of these modified NPs to reach the brain was evaluated in rats after intravenous administration. The g21 was linked on the surface of NPs labeled with tetramethylrhodamine by means of the Avidin-Biotin technology. The g21-labeled NPs were injected into the tail vein of rats and, after animal sacrifice, the brain localization was evaluated by confocal microscopy, fluorescence microscopy and electron microscopy. Studies to evaluate the biodistribution of the g21-modified NPs in comparison to the unmodified NPs were also carried out. Moreover, to confirm the absence of any anorectic effect of g21 linked on the surface of NPs, appropriate studies were used to assess the rats. After intravenous administration, the g21-modified NPs were able to cross the blood-brain barrier and to enter the brain parenchyma. The biodistribution studies of both unmodified and modified NPs pointed out an uptake at liver and spleen level, whereas only the g21-modified NPs showed brain localization. The food-intake experiments pointed out that the intravenous administration of g21 conjugated to the NP surface did not produce any anorectic effect in the rats. g21-modified NPs were able to cross the blood-brain barrier. These new modified NPs could be effectively considered as useful carrier systems for brain drug delivery.


  • Sialic acid and glycopeptides conjugated PLGA nanoparticles for central nervous system targeting: In vivo pharmacological evidence and biodistribution

    by G. Tosi, A.V. Vergoni, B. Ruozi, L. Bondioli, L. Badiali, F. Rivasi, L. Costantino, F. Forni, M.A. Vandelli


  • Glycopeptide-Decorated Nanoparticles as Drug Carriers for CNS: Effects of Surface Coverage and Carbohydrate Type

    by G. Tosi, L. Costantino, F. Rivasi, B. Ruozi, L. Bondioli, A. V. Vergoni, R. Tacchi, A. Bertolini, M. A. Vandelli, F. Forni

    In order to study the ability of peptide-decorated PLGA Np to act as CNS drug delivery agents, the effect of various degrees of Np surface coverage by the peptide H2N-Gly-L-Phe-D-Thr-Gly-L-Phe-L-Leu-L-Ser(O-R)-CONH2 (R = -D-glucose) and of the type of carbohydrate present on Ser (R = H, -D-glucose, -D-xylose, -D-lactose, α-D-Mannose) were evaluated. Loperamide was used as a model drug and its presence on rat CNS was evaluated by means of its pharmacological effect (antinociceptive assay, hot-plate test). The pharmacological effect exerted by loperamide loaded into Np demonstrated to be strongly dependent on the degree of peptidic surface coverage of Np. Thus, in the presence of a high surface coverage, a very short effect is observed, which appears early on (0.5 min) after Np i.v. administration. Moreover, the sugar moiety influences markedly the CNS effect of loperamide loaded into the peptide-decorated Np: among the carbohydrates here examined, the presence of -D-glucose on the Ser of the peptide showed the best results, both in terms of the maximum effect and length.

  • Nanoparticles as drug delivery agents specific for CNS: in vivo biodistribution

    by Anna Valeria Vergoni, Giovanni Tosi, Raffaella Tacchi, Maria Angela Vandelli, Alfio Bertolini, Luca Costantino


  • Chronic treatment with polychlorinated biphenyls (PCB) during pregnancy and lactation in the rat

    by A. Colciago, L. Casati, O. Mornati, A.V. Vergoni, A. Santagostino, F. Celotti, P. Negri-Cesi


  • Regulation of hypothalamic endocannabinoid levels by neuropeptides and hormones involved in food intake and metabolism: Insulin and melanocortins

    by Isabel Matias, Anna Valeria Vergoni, Stefania Petrosino, Alessandra Ottani, Alessandro Pocai, Alfio Bertolini, Vincenzo Di Marzo


  • Targeting the central nervous system: In vivo experiments with peptide-derivatized nanoparticles loaded with Loperamide and Rhodamine-123

    by G. Tosi, L. Costantino, F. Rivasi, B. Ruozi, E. Leo, A.V. Vergoni, R. Tacchi, A. Bertolini, M.A. Vandelli, F. Forni


  • Open Access

    Similarities and Differences Between Chronic Migraine and Episodic Migraine

    by Anna Ferrari, Sheila Leone, Anna Valeria Vergoni, Alfio Bertolini, Grazia Sances, Ciro Pio Rosario Coccia, Alessandra Ottani, Diego Pinetti, Emilio Sternieri

    Objective.—To quantify and characterize the similarities and the differences between chronic migraine (CM) patients with medication overuse and episodic migraine (EM) patients with only occasional analgesic use.Background.—Population‐level epidemiology, characteristics, mechanisms of chronic daily headache, and medication‐overuse headache have been widely studied but patient characteristics have received less attention.Methods.—We compared sociodemographic data, family history, physiological and medical history, health services utilized, drugs taken/prescribed, and outcome of 2 groups of subjects: 150 patients, suffering from CM, complicated by probable medication‐overuse headache (CM group), consecutively admitted during 2005 to the inpatients' ward of the Headache Centre of the University Hospital of Modena and Reggio Emilia, Italy, to undergo withdrawal from their overused medications; 100 patients suffering from EM, uncomplicated by medication overuse (EM group), consecutively referred to the outpatients' ward of the Headache Centre during November and December 2005.Results.—All sociodemographic characteristics were significantly different between the 2 groups. As a whole, the CM group began to suffer from migraine earlier than the EM group. Drug and/or alcohol abuse was significantly higher among first‐degree relatives of CM (19%) than of EM (6%) patients. The most frequent comorbid disorders were psychiatric (67%) and gastrointestinal diseases (43%) in the CM group, and allergies in the EM group (31%). Seventy percent of CM patients and 42% of EM patients were taking daily at least another drug, besides those for headache treatment. Most overused medications in the CM group were triptans (43%); the EM group used above all single NSAIDs (56%). At 3‐month follow‐up, prophylactic treatments reduced, by at least 50%, the frequency of headache in about three‐fourths of patients of both the groups; however, headache remained significantly more frequent in the CM than in EM group: only a minority (15%) of CM patients reverted to a headache frequency comparable to that of the EM group.Conclusions.—CM patients present more multiple comorbid disorders, polypharmacy, and social impediments than EM patients. These associated conditions complicate CM clinical management. Even after withdrawal from medication overuse, CM could not be completely reverted by current prophylactic treatments.